Evidence map›Paper›PMID 34733068›Full record

ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2021

Comparison of Adverse Events With Vancomycin Diluted in Normal Saline vs Dextrose 5.

Robert C Ross, Bridgette A Kelly, Rachel M Smith, Andrew J Franck

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Robert C Rossis a Clinical Pharmacy Fellow, is a Pharmacy Resident, is a Pharmacy Resident, and is a Clinical Pharmacy Specialist at the North Florida/South Georgia Veterans Health System in Gainesville, Florida.
Bridgette A Kellyis a Clinical Pharmacy Fellow, is a Pharmacy Resident, is a Pharmacy Resident, and is a Clinical Pharmacy Specialist at the North Florida/South Georgia Veterans Health System in Gainesville, Florida.
Rachel M Smithis a Clinical Pharmacy Fellow, is a Pharmacy Resident, is a Pharmacy Resident, and is a Clinical Pharmacy Specialist at the North Florida/South Georgia Veterans Health System in Gainesville, Florida.
Andrew J Franckis a Clinical Pharmacy Fellow, is a Pharmacy Resident, is a Pharmacy Resident, and is a Clinical Pharmacy Specialist at the North Florida/South Georgia Veterans Health System in Gainesville, Florida.
North Florida/South Georgia Veterans Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIV vancomycin is widely used for infections caused by Gram-positive bacteria; however, nephrotoxicity is commonly associated with its use. Clinical trials have shown an increased incidence of acute kidney injury (AKI) using normal saline (NS) for fluid resuscitation. This study evaluated differences in AKI and other patient outcomes associated with vancomycin diluted in NS compared with dextrose 5% in water (D5W).

methodsThis retrospective cohort study conducted at a single US Department of Veterans Affairs hospital included veterans who received vancomycin for at least 48 hours between July 1, 2015 and June 30, 2020. This study compared adverse events (AEs) of patients receiving vancomycin diluted in either NS or D5W. The primary outcome was incidence of AKI. Secondary outcomes included incidence of hyperglycemia, hyperchloremia, hypernatremia, metabolic acidosis, in-hospital mortality, and 30-day posthospitalization mortality.

resultsThe study included 123 patients in each group (N = 246). The percentage of AKI was 22.8% in the D5W group compared with 14.6% the NS group (

conclusionsThis study comparing the AEs of IV vancomycin diluted in NS and D5W found no significant differences in AKI or other patient outcomes. These study results do not suggest the crystalloid used to dilute IV vancomycin is associated with differences in nephrotoxicity or other relevant AEs.

Identifiers

PMID34733068
PMCPMC8560101
OpenAlexW3207985878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.